Timely detection of a potentially fatal chronic liver disease that one out of fo...
Timely detection of a potentially fatal chronic liver disease that one out of four of us have without knowing it.
Evido is a health tech company that originates from the clinical world and stands on top of more than a decade of extensive clinical research from the elite Center of Liver Research at Odense University Hospital. We are a team of...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PTQ-16-08581
Desarrollo de nuevas herramientas para la mejora del diagnós...
30K€
Cerrado
EMIF
European Medical Information Framework
56M€
Cerrado
STRIMHealth
Strengthening Translational Research for Improved Metabolic...
1M€
Cerrado
TIN2017-85949-C2-1-R
INFRAESTRUCTURA Y TECNOLOGIAS DE INTEROPERABILIDAD PARA APLI...
75K€
Cerrado
RTC-2016-5418-1
ELABORACIÓN E IMPLEMENTACIÓN DE HERRAMIENTAS DE ESTRATIFICAC...
234K€
Cerrado
PTQ2020-010948
Desarrollo de una plataforma para la integración de datos re...
52K€
Cerrado
Información proyecto LiverPRO
Duración del proyecto: 12 meses
Fecha Inicio: 2023-05-31
Fecha Fin: 2024-05-31
Líder del proyecto
EVIDO APS
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
75K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Evido is a health tech company that originates from the clinical world and stands on top of more than a decade of extensive clinical research from the elite Center of Liver Research at Odense University Hospital. We are a team of hepatologists, clinical researchers, data geeks, venture builders and healthcare innovators. All sharing a common goal to help people at risk of Chronic Liver Disease by re-inventing diagnostics with evidence-based and data-driven solutions. Our mission is to ensure timely detection and support of at-risk people that unknowingly have a potential fatal disease.
We see the Women TechEU programme as a great opportunity that will front load our commercial traction and accelerate our time to market. Up to this point we have achieved to attract funding to cover our product development cost and regulatory affair. We have achieved to set up international collaborations to mature our data model and test our solution. All key activities to get LiverPRO to market and accelerate our adoption.
To build on this traction and ensure a holistic perspective on our business, we want to broaden our activities and start frontloading our commercial activities already in the beginning of 2023. We see Women TechEU as a brilliant programme to support us in doing exactly this. Women TechEU can give us a resource boost to expand our focus and enable us to pursue commercial traction in parallel to getting LiverPRO to the market. We see a huge value in being part of the mentoring and coaching part of the programme and could really benefit from getting input on roll-out strategy, pricing, sales processes, pilot sales, etc. The combination of both financial support and specific coaching will help us accelerate our commercial traction and build a robust go-to-market strategy.